ProBiotix Health plc (‘ProBiotix’), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a new commercial partnership with Mexico-based raw materials and ingredients specialist, Raff.

Founded in 1999, Raff is a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors. The company’s expertise is backed by a highly trained technical team, specialising in the use and application of lactic and probiotic cultures, rennet, enzymes, and preservatives.

The five-year agreement enables Raff to act in partnership with ProBiotix, as the exclusive distributor of LP_LDL^® to be used as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026.

Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths.

Moreover, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol. The movement from ‘cure’ towards ‘prevention’ provides a strong backdrop for the fast-growing supplement market, which should lead to a good sales opportunity for ProBiotix.

Steen Andersen, CEO of ProBiotix, commented: “After lengthy discussions, we are delighted to announce our partnership with Raff. We firmly believe that they share our ethos: to develop innovative products to help enrich individuals with healthier lives.

“The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target.”

Rafael Gonzalez, Commercial Director of Raff, added: “We are a well-established probiotics supplier in the Mexican market through our relationship with Italy-based Sacco Systems. The opportunity to partner with ProBiotix Health, a pioneer in probiotics and cardiometabolic health, is extremely exciting for us.

“We welcome the opportunity to expand our portfolio with a unique well-documented precision biotic like LP_LDL^®. We believe that LP_LDL^® fills an untapped potential in the fast-growing Mexican supplement market and that the product sits well with our already strong position in the sector.”